What is the evidence that aspirin reduces the risk of malignant transformation in pouch adenomas in patients with FAP
Out of scope for this tool. The focus of this literature tool is the surgical management of IBD. For medical management and drug dosing, please see ChatIBD.com.
no. There is no convincing evidence that routine aspirin reduces malignant transformation of pouch adenomas in FAP. no retrieved study measured cancer or malignant transformation in ileal-pouch adenomas as an endpoint; the aspirin data concern suppression of colorectal polyp recurrence/size in patients with intact colons, not the pouch, and even those show mixed results 1–3. 1–4
What is known: - The J-FAPP Study IV RCT showed low-dose aspirin safely suppressed recurrence of colorectal polyps larger than 5 mm in FAP patients without prior colectomy, a polyp endpoint, not cancer or pouch. 2,4 - A narrative review concluded there is no strong evidence that aspirin significantly reduces disease progression in FAP, with any colorectal-cancer effect emerging only after ~10 years in other populations. 1 - CAPP1 (206 FAP patients, intact colons) found no significant reduction in polyp count or size with aspirin, only a non-significant trend, and effectiveness in FAP remains unclear. 3
What is unknown / caveats: - J-FAPP IV showed polyp suppression whereas CAPP1 showed no significant reduction - Aspirin's colorectal-cancer signal in other familial/general populations only emerges after ~10 years - No retrieved study assessed aspirin effect in the ileal pouch after IPAA or after IRA - Endpoints are polyp recurrence/size, not malignant transformation or cancer incidence - J-FAPP trial used ~8-month treatment in Japanese patients; long-term and cross-ethnic effects unstudied - The pouch-specific question is essentially unaddressed by the retrieved literature.
## References
1. PMID: 32507936. (metadata not in corpus)
2. Ishikawa H, Mutoh M, Sato Y, Doyama H, Tajika M, Tanaka S, Horimatsu T, Takeuchi Y, Kashida H, Tashiro J, Ezoe Y, Nakajima T, Ikematsu H, Hori S, Suzuki S, Otani T, Takayama T, Ohda Y, Mure K, Wakabayashi K, Sakai T. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol. 2021;6:474-481. PMID: 33812492.
3. PMID: 22122775. (metadata not in corpus)
4. Saito E, Mutoh M, Ishikawa H, Kamo K, Fukui K, Hori M, Ito Y, Chen Y, Sigel B, Sekiguchi M, Hemmi O, Katanoda K. Cost-effectiveness of preventive aspirin use and intensive downstaging polypectomy in patients with familial adenomatous polyposis: A microsimulation modeling study. Cancer Med. 2023;12:19137-19148. PMID: 37649281.
For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.
---
_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._
Reviewer notes